Patents Examined by Tara L Martinez
  • Patent number: 11149078
    Abstract: The application concerns tissue inhibitor of metalloproteinase 3 (TIMP-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of TIMP-3 with specific amino acid substitutions in order to introduce N-linked glycosylation sites.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 19, 2021
    Assignee: Amgen Inc.
    Inventors: Jason C. O'Neill, Randal R. Ketchem, Taeweon Lee, Vishnu Chintalgattu, Jennitte Leann Stevens
  • Patent number: 11150251
    Abstract: The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: October 19, 2021
    Assignees: Clemson University Research Foundation, MUSC Foundation for Research Development
    Inventors: Ying Mei, Jia Jia, Chung-Jen James Chou
  • Patent number: 11124542
    Abstract: Modulators of melanocortin receptors (MCR) are provided herein. An MC5R peptide ligand is represented by to Formula 1: R1-Nle4-c[Xaa5-Yaa6-(NMe)D-Nal(2?)7-Arg8-Trp9-(NMe)Zaa10]-R2. R1 can be an acetyl, a glycosylated amino acid, —CO—(CH2)nCH3, or —CO—(CH2)nCF3 with n ranging from 1 to 6. R2 can be an —CONH2, —COOH, or —CH2OH. Xaa, Yaa, and Zaa can each be a natural amino acid or an unnatural amino acid.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: September 21, 2021
    Inventors: Victor J. Hruby, Minying Cai
  • Patent number: 11116868
    Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: September 14, 2021
    Inventors: Michael Sander, Harald Potzschke
  • Patent number: 11116816
    Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: September 14, 2021
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Patent number: 11110152
    Abstract: Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: September 7, 2021
    Inventors: Julie Ledford, Monica Kraft
  • Patent number: 11103561
    Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: August 31, 2021
    Assignee: Hamlet Pharma AB
    Inventors: Catharina Svanborg, Manoj Puthia, Chin Shing Ho
  • Patent number: 11098097
    Abstract: Disclosed are recombinant polypeptides that include (a) a filaggrin amino acid sequence and (b) a cell importation signal sequence that includes a motif of two to fifteen amino acids, wherein the motif includes at least one arginine residue and at least one methionine residue. Also disclosed are nucleic acids encoding the recombinant polypeptides of the present invention, and compositions that include the recombinant polypeptides and nucleic acids of the present invention. Methods of treating or preventing a skin disease or skin disorder using the compositions of the present invention are also included, as well as kits that include a sealed containing that includes a recombinant polypeptide of the present invention.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: August 24, 2021
    Assignee: Research Development Foundation
    Inventors: J. Timothy Stout, Binoy Appukuttan, Trevor McFarland
  • Patent number: 11091771
    Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest, as probes for the isolation of other homologous (or partially homologous) genes. The insecticidal proteins find use in controlling, inhibiting growth or killing lepidopteran, coleopteran, dipteran, fungal, hemipteran, and nematode pest populations and for producing compositions with insecticidal activity.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: August 17, 2021
    Inventors: Ruth Cong, Jingtong Hou, Zhenglin Hou, Phillip A. Patten, Takashi Yamamoto
  • Patent number: 11083726
    Abstract: The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: August 10, 2021
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Robert A. Steiner, Charles Chavkin, Donald K. Clifton, Susan Reed, Victor Navarro
  • Patent number: 11020482
    Abstract: Disclosed herein are compositions and methods for inhibiting viral entry.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: June 1, 2021
    Inventors: J. Nicholas Francis, Joseph S. Redman, Michael S. Kay
  • Patent number: 11020462
    Abstract: We describe peptides and their uses for the treatment of, e.g. acute myocardial infarction and other cytokine storm-associated conditions.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: June 1, 2021
    Assignee: SERPIN PHARMA
    Inventor: Cohava Gelber
  • Patent number: 11007249
    Abstract: The present invention relates to methods of treating a subject suffering from or at risk of suffering from graft versus host disease (GvHD) comprising administering a therapeutically effective amount of at least one of pregnancy specific glycoprotein 1 (PSG1) or PSG9 to a subject in need thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 18, 2021
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gabriela Dveksler, Harry Malech
  • Patent number: 11001624
    Abstract: The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: May 11, 2021
    Assignees: VIB VZW, UniversiteitGent
    Inventors: Savvas Savvides, Rudi Beyaert, Kenneth Verstraete, Harald Braun, Frank Peelman
  • Patent number: 11001822
    Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: May 11, 2021
    Assignee: Wellstat ImmunoTherapeutics, LLC
    Inventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
  • Patent number: 10995128
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 4, 2021
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 10967068
    Abstract: The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 6, 2021
    Inventors: Russell George Dushin, Pavel Strop, Magdalena Grazyna Dorywalska, Ludivine Moine
  • Patent number: 10960055
    Abstract: Undue scarring of healing wounds is decreased and/or the relapse rate of wounds is lowered by applying a composition that includes hemoglobin to the wound area. At least 40% of the hemoglobin in the composition is provided in CO-charged form.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: March 30, 2021
    Inventor: Michael Sander
  • Patent number: 10940216
    Abstract: Described herein are cyclic peptides, nanoparticles bound with cyclic peptides, and methods for using said cyclic peptides and/or said nanoparticles bound with cyclic peptides for intraoperative nerve tissue imaging.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: March 9, 2021
    Assignees: Cornell University, Memorial Sloan Kettering Cancer Center
    Inventors: Michelle S. Bradbury, Barney Yoo, Ulrich Wiesner, Peiming Chen, Kai Ma, Snehal G. Patel, Daniella Karassawa Zanoni
  • Patent number: 10913781
    Abstract: Disclosed here is the rational design and use of potent and specific GPCR antagonist pepducins based on GPCR regions such as the third intracellular loop and adjacent regions.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: February 9, 2021
    Assignee: Tufts Medical Center, Inc.
    Inventors: Athan Kuliopulos, Lidija Covic